(NASDAQ:ARRY) on Friday, June 3 with "Buy" rating. As per Friday, May 20, the company rating was maintained by Barclays Capital. (NASDAQ:ARRY) has "Buy" rating given on Tuesday, May 30 by Cantor Fitzgerald. Deutsche Bank maintained Dynegy Inc. (NASDAQ:ARRY) on Wednesday, August 9 with "Buy" rating. The company was maintained on Thursday, August 24 by Jefferies. (NYSE:WSO) on Wednesday, June 1 with "Positive" rating. Leerink Swann maintained Array BioPharma Inc. (NYSE:DYN) on Friday, October 16 with "Neutral" rating. The stock has "Hold" rating by Deutsche Bank on Tuesday, April 26. (NASDAQ:ARRY) for 343,559 shares. The stock decreased 3.56% or $0.625 during the last trading session, reaching $16.925. (NASDAQ:LOPE) by 142,121 shares in the quarter, leaving it with 2.34 million shares, and cut its stake in Veeva Systems Inc.
Array BioPharma Inc. (NASDAQ:ARRY) may have great momentum, but how has it been performing relative to the market? It has outperformed by 159.81% the S&P500. Geode Mgmt Limited owns 1.78M shares or 0.01% of their United States portfolio. Its down 0.01, from 0.9 in 2017Q2. It is positive, as 21 investors sold Dynegy Inc. shares while 39 reduced holdings. 49 funds opened positions while 104 raised stakes. Amg National Trust Bank reported 93,033 shares. Sei owns 8,442 shares. Principal Fincl Gp has invested 0.02% in Watsco, Inc. Narrowing our focus to the previous 1 month, the shares have been down by -5.47%. Jane Street Gp Ltd Liability owns 47,930 shares for 0% of their portfolio. Alliancebernstein Lp reported 0% in Array BioPharma Inc. Moreover, Bokf Na has 0.03% invested in Watsco, Inc. (NYSE:CPS) is presently 2.25.
Let's shift the focus and look at some historical stock price action on shares of Cooper-Standard Holdings Inc. Orbimed Advisors Ltd reported 14.18M shares. Ecor1 Cap Limited Com reported 1.25M shares. Northwestern Mutual Wealth holds 0% in Dynegy Inc. (NYSE:TPR) is noted at 1.32. The stock has a market capitalization of $3,360.00, a price-to-earnings ratio of -22.12 and a beta of 2.03. It now has negative earnings. Since the beginning of the calendar year, we can see that shares have changed -5.99%. Ally Fin holds 50,000 shares or 0.51% of its portfolio. Array BioPharma Inc. (NASDAQ:ARRY) has risen 176.51% since February 7, 2017 and is uptrending. It has underperformed by 7.95% the S&P500. Washington Com invested 1.62% in Watsco, Inc. Its up 0.05, from 1.16 in 2017Q2. Haddock Jason also sold $102,975 worth of Array BioPharma Inc. 41 funds opened positions while 52 raised stakes. Its down 15.26% from 121,900 shares previously. UBS Asset Management Americas Inc. increased its position in Array BioPharma by 172.9% during the fourth quarter. (NASDAQ:ARRY) shares were sold by Squarer Ron. 18,813 were accumulated by Bnp Paribas Arbitrage. Cubist Systematic Strategies Ltd Liability Co invested 0.01% of its portfolio in Array BioPharma Inc. During the same quarter in the previous year, the business posted ($0.14) earnings per share. equities research analysts expect that Array BioPharma will post -0.99 EPS for the current fiscal year. (NASDAQ:ARRY) on Tuesday, February 6 with "Buy" rating. (VVV), during the trading sessions, it is clear to see that the prices of their shares moved to $23.62. SunTrust Banks also issued estimates for Array BioPharma's Q3 2018 earnings at ($0.27) EPS, Q4 2018 earnings at ($0.29) EPS, FY2018 earnings at ($0.95) EPS, FY2019 earnings at ($0.92) EPS, FY2020 earnings at ($0.37) EPS, FY2021 earnings at $0.14 EPS and FY2022 earnings at $0.82 EPS. If TripAdvisor, Inc. (NASDAQ:TRIP) shares can stay above the price resistance around $43.18 a share, that could help propel TripAdvisor, Inc. D E Shaw & has 164,933 shares. This is the consensus number according to data provided by Zacks Research. Therefore 67% are positive. Array BioPharma had 33 analyst reports since June 3, 2016 according to SRatingsIntel. The Stock has YTD (year to date) performance of 31.8 percent. (NASDAQ:ARRY) earned "Buy" rating by Jefferies on Monday, August 29. The direction of this stock is getting Strongest.This is an indicator for investors to know whether the stock is heading towards a Buy or Sell, or whether the Hold is advancing towards a Buy or a Sell. The firm has "Outperform" rating given on Wednesday, September 2 by Credit Suisse. Cowen & Co has "Buy" rating and $15.0 target. The company was maintained on Thursday, October 26 by Morgan Stanley. Stifel Nicolaus reiterated a "buy" rating on shares of Array BioPharma in a research note on Wednesday, November 1st. The firm has "Buy" rating by Piper Jaffray given on Wednesday, May 31.
Since September 29, 2017, it had 0 buys, and 6 insider sales for $13.29 million activity. (NASDAQ:ARRY). 44,706 are owned by Dupont Cap Management. $493,510 worth of Array BioPharma Inc. 282,874 shares valued at $3.03 million were sold by Robbins Andrew R on Saturday, December 16. However, if the ARRY shares go below $13.33 then it would indicate a much weaker market for the company. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). The Company's drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.